Results 221 to 230 of about 191,017 (312)

Prolactin and oxytocin as modulators of intestinal contractility and glucose uptake. [PDF]

open access: yesFront Physiol
Figueroa-Carrasco PA   +2 more
europepmc   +1 more source

Loss of VMP1 Impairs Tight Junction Recycling and Aggravates Intestinal Barrier Dysfunction in Inflammatory Bowel Disease

open access: yesAdvanced Science, Volume 13, Issue 25, 4 May 2026.
This study identifies vacuole membrane protein 1 (VMP1) as a critical regulator of intestinal epithelial barrier homeostasis. VMP1 facilitates the recruitment of CORO1C to late endosomes, supporting Retromer‐mediated recycling of the tight junction protein Occludin.
Jiawei Zhao   +12 more
wiley   +1 more source

Influence of graft perfusion pressure on graft viability after small bowel preservation and transplantation [PDF]

open access: yes, 1996
Galvao, FHF   +6 more
core  

Glucuronolactone Promotes Mucin Sulfation to Alleviate Deoxynivalenol‐Induced Intestinal Injury via Microbiota‐Dependent and ‐Independent AHR Activation

open access: yesAdvanced Science, Volume 13, Issue 25, 4 May 2026.
Glucuronolactone (GLU) as a natural metabolite of glucose, increases Lactobacillus amylovorus abundance and luminal IAA level to activate AHR signaling. In addition, GLU itself can directly elevate AHR signaling activity independently of microbiota and IAA.
Chenbin Cui   +8 more
wiley   +1 more source

Jejunum vs ileum

open access: yes, 2016
Henry Knipe   +2 more
openaire   +1 more source

Noonan Syndrome Spectrum Disorders Predispose to Systemic Lupus Erythematosus: Case Report and Critical Review of the Literature

open access: yesAmerican Journal of Medical Genetics Part A, Volume 200, Issue 5, Page 1091-1097, May 2026.
ABSTRACT RASopathies are clinically overlapping neurodevelopmental syndromes resulting from germline mutations in genes involved in the rat sarcoma/mitogen‐activated protein kinases (RAS/MAPK) pathway. Historically, RASopathies have been described by clinical phenotypes, such as Noonan syndrome and Neurofibromatosis type I.
Anastasia‐Vasiliki Madenidou   +6 more
wiley   +1 more source

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1309-1325, May 2026.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy